Introduction {#S0001}
============

The inhaled corticosteroids (ICS) are widely used as a basic regimen of pharmacological treatment in asthma \[[@CIT0001]--[@CIT0004]\]. The main goal of their use is to attenuate an inflammatory reaction within the respiratory tract. However, ICS are also supposed to protect from airway remodeling in chronic inflammatory diseases, especially in asthma and chronic obstructive pulmonary disease \[[@CIT0005], [@CIT0006]\]. Among various factors involved in both, inflammation and airway remodeling, are matrix metalloproteinases (MMPs), mainly MMP-9 \[[@CIT0007]--[@CIT0010]\].

It has been proven that patients with asthma, when compared to healthy controls, revealed increased concentration and activity of MMP-9 in sputum, bronchoalveolar lavage fluid, airway mucosal biopsies, or exhaled breath condensates (EBC) \[[@CIT0011]--[@CIT0013]\]. Moreover, the MMP-9 levels were shown to correlate with severity of disease \[[@CIT0014]--[@CIT0016]\].

Although corticosteroids were suggested to influence MMP-9 production \[[@CIT0017], [@CIT0018]\], the exact mechanism of their action regarding this issue is still unclear. Possibly, corticosteroids may control MMP-9 by direct modulation of its expression \[[@CIT0019], [@CIT0020]\]. On the other hand, they are known to attenuate inflammatory response, and thus may also modify the level and activity of MMP-9 in the respiratory tract indirectly \[[@CIT0021]\].

Since the anti-inflammatory action of ICS may be assessed by measurement of local concentrations of selected pro-inflammatory cytokines, e.g. interleukin (IL)-8 and tumor necrosis factor (TNF), we have selected both cytokines as markers of inflammatory reaction \[[@CIT0022]\]. Therefore, the aim of our proof of concept study was to analyze the impact of increased doses of inhaled corticosteroids on the concentration and activity of MMP-9 in exhaled breath condensates of patients with allergic asthma exacerbation. This influence was measured in the context of exhaled nitric oxide (eNO) and two pro-inflammatory cytokines, IL-8 and TNF.

Material and methods {#S0002}
====================

Patients {#S20003}
--------

This pilot study involved a very small group of 4 teenager patients (aged 14.0 ±3.4 years) with asthma exacerbation, presumably following natural allergen exposure, diagnosed according to GINA guidelines (Global Initiative for Asthma, Strategy for Asthma Diagnosis and Prevention; <http://www.ginasthma.org>) \[[@CIT0001], [@CIT0023]\]. Prior to exacerbation, all patients from the study group were treated using low doses of ICS, which formerly allowed to control symptoms on the satisfactory level \[[@CIT0024], [@CIT0025]\].

The control group comprised 6 healthy age-matched individuals attending the outpatient clinic for routine control visits.

The concept of the study was reviewed and approved by the local bioethics committee. The study procedures conformed to the ethical guidelines of the World Medical Association Declaration of Helsinki. All patients and their parents gave the informed consent to participate in the study.

Clinical assessment {#S20004}
-------------------

All children underwent the routine clinical examination and additional laboratory tests at the recruitment (considered as a baseline). The peripheral blood morphology, analysis of serum total IgE levels and skin tests were done to verify the allergic origin of asthma. The severity of asthma exacerbation was evaluated based on clinical symptoms (shortness of breath, decreased exercise tolerance and wheeze, also occurring in the night), results of spirometric test and the level of exhaled nitric oxide (eNO). The spirometry was performed using Lungtest 1000 (MES, Krakow, Poland). The assessed parameters included forced expiratory volume in the first second (FEV~1~) and the Tiffeneau-Pinelli index. The eNO was measured using Sievers NO 280 equipment (GE Analytical Instruments, Boulder, CO).

In addition to routine clinical evaluation and eNO measurement, the exhaled breath condensates were collected using ECoScreen condenser (Jäger, Hoechberg, Germany) \[[@CIT0026], [@CIT0027]\]. The EBC samples (approx. 700-1000 µl from each collection) were immediately frozen and maintained at --70°C for further analysis.

Treatment {#S20005}
---------

The patients with asthma exacerbation have received inhaled corticosteroid (fluticasone propionate) in a daily dose of 500-1000 µg, with 100 µg of long acting β2-agonist (salmeterol), twice a day. After 4 weeks of treatment, the clinical assessment, eNO measurement and EBC collection were repeated in the patients group and the results were compared to these from the baseline and to the control group.

Analysis of exhaled breath condensates {#S20006}
--------------------------------------

The concentrations of selected cytokines (IL-8 and TNF) in breath condensates were measured using Ultrasensitive ELISA sets for human IL-8 and TNF (both from Invitrogen, Camarillo, CA). The tested samples were analyzed using the Microplate Reader 550 (BIO-RAD, Hercules, CA). Based on the respective standard calibration curve, the absorbance of each sample was converted to the concentration of the corresponding cytokine and expressed in pg per ml of EBC. The assay sensitivity for both cytokines was 0.1 pg/ml.

The total amount of MMP-9 and its actual enzymatic activity in breath condensates were assessed using a novel immunoenzymatic test -- QuickZyme Human MMP-9 activity assay (QuickZyme BioSciences, Leiden, Netherlands). The test was done according to the protocol provided by the manufacturer. The absorbance of analyzed samples was measured by Microplate Reader 550 (BIO-RAD) directly after addition of substrate (T~0~) and then after 1 hour of incubation at 37°C (T~1~). The MMP-9 concentrations (expressed in ng/ml), both active and total, were calculated based on the standard calibration curve of pre-activated human recombinant MMP-9, with the assay sensitivity of 0.01 ng/ml.

To monitor the possible EBC contamination by MMP-9 from saliva, 5 randomly selected samples were screened for the presence of amylase \[[@CIT0028]--[@CIT0030]\].

Results {#S0007}
=======

When compared to the baseline, after 4 weeks of treatment with increased doses of ICS in all individuals from asthma group we have observed the satisfactory reduction of clinical symptoms. It included improved exercise tolerance, reduction of breath shortness and significant wheeze relief. Mentioned changes were accompanied by an improvement in patients' spirometric scores, as found in FEV1 measurements ([Fig. 1](#F0001){ref-type="fig"}) and Tiffeneau-Pinelli index ([Fig. 2](#F0002){ref-type="fig"}). No clinically relevant adverse events, attributed to increased doses of ICS, were observed in the patients group during the study period. Clinical details of patients, results of their blood tests, total IgE and skin tests are shown in [Table 1](#T0001){ref-type="table"}.

![The results of forced expiratory volume in the first second (FEV~1~) measured in patients with asthma exacerbation (before or after inhaled corticosteroids treatment, respectively) and control individuals. The results were expressed in liters per minute (l/min). Each dot represents measurement done in single patient from the respective group. Horizontal lines correspond to mean (bold line) and median (thin line) values for each group. Dashed lines connect respective "before ICS" and "after ICS" values corresponding to their changes following the treatment with inhaled corticosteroids in each patient](CEJI-41-27905-g001){#F0001}

![The results of Tiffeneau-Pinelli index calculated in patients with asthma exacerbation (before or after ICS, respectively) and control individuals. The results of calculation were expressed in percent (%). Each dot represents results from a single patient in the respective group. Horizontal lines correspond to mean (bold line) and median (thin line) values for each group. Dashed lines connect respective "before ICS" and "after ICS" values corresponding to their changes following the treatment with inhaled corticosteroids in each patient](CEJI-41-27905-g002){#F0002}

###### 

Selected clinical parameters of patients in the asthma and control group

  ------------------------------------------------------------------------------
  Parameter/Patient group                     Asthma          Healthy control°
  ------------------------------------------- --------------- ------------------
  Age (years)\                                14.0 ±3.4\      12.9 ±3.8\
  Sex distribution (male / female)\           3/1\            4/2\
  Eosinophil percent (%)\                     8.3 ±3.8\       1.5 ±1.1\
  Total IgE (kU/l)\                           616.3 ±593.9\   35.1 ±7.4\
  Positive skin tests (number of patients)\   4\              0\
   *Grass pollens*\                           2\              --\
   *Rye pollen*\                              2\              --\
   *Birch pollen*\                            1\              --\
   *Dust mite*\                               4\              --\
   *Cat\'s dander*\                           2\              --\
   *Alternaria*                               2               --

  ------------------------------------------------------------------------------

In all patients with asthma exacerbation, the initial eNO levels were higher than in healthy controls (73.0 ±30.3 ppb vs. 16.8 ±6.6 ppb). After 4 weeks of intense ICS treatment, in all patients the eNO concentration in exhaled air was apparently lower, as compared to baseline. Nevertheless, the mean eNO level (26.9 ±15.1 ppb) still remained higher than in the control group ([Fig. 3](#F0003){ref-type="fig"}).

![The results of exhaled nitric oxide (eNO) assessed in patients with asthma exacerbation (before or after ICS, respectively) and control individuals. The results were expressed in particles per billion (ppb). Each dot represents measurement done in a single patient from the respective group. Horizontal lines correspond to mean (bold line) and median (thin line) values for each group. Dashed lines connect respective "before ICS" and "after ICS" values corresponding to their changes following the treatment with inhaled corticosteroids in each patient](CEJI-41-27905-g003){#F0003}

Similarly to eNO, the mean initial concentration of TNF/EBC in the asthma group was higher than in healthy controls (3.5 ±1.8 pg/ml vs. 2.3 ±0.9 pg/ml). After 4 weeks of ICS treatment in all patients we have observed a noticeable decrease in TNF/EBC to the mean level of 1.5 ±1.0 pg/ml ([Fig. 4](#F0004){ref-type="fig"}).

![The results of measurement of TNF concentration in exhaled breath condensate (TNF/EBC) in patients with asthma exacerbation (before or after ICS, respectively) and control individuals. The results were expressed in picograms per milliliter (pg/ml). Each dot represents measurement done in a single patient from the respective group. Horizontal lines correspond to mean (bold line) and median (thin line) values for each group. Dashed lines connect respective "before ICS" and "after ICS" values corresponding to their changes following the treatment with inhaled corticosteroids in each patient](CEJI-41-27905-g004){#F0004}

The concentration of IL-8 in both, patients and healthy controls, was below the detection limit (i.e. \< 0.1 pg/ml) in all EBC samples.

The mean concentration of total MMP-9 in breath condensates was significantly higher in the asthma group than in healthy controls (12.6 ±7.4 pg/ml vs. 3.6 ±1.6 pg/ml). Noteworthy, after 4 weeks with increased doses of ICS, the mean MMP-9/EBC concentration in treated patients did not change significantly (12.6 ±7.4 pg/ml to 14.0 ±5.9 pg/ml). Interestingly, although in one patient the concentration of total MMP-9/EBC increased considerably, nevertheless in three other individuals it remained on the baseline level ([Fig. 5](#F0005){ref-type="fig"}). The analysis in respect of actual activity of MMP-9 in breath condensates has shown that the calculated levels of its active fraction corresponded to approximately 70-80% of total MMP-9 concentration. However, the same trend, as for total MMP-9, was observed in case of active MMP-9 regarding its concentration changes in course of intense ICS treatment (data not shown).

![The results of assessment of total MMP-9 concentration in exhaled breath condensate (MMP-9/EBC) in patients with asthma exacerbation (before or after ICS, respectively) and control individuals. The concentration of total MMP-9 was extrapolated from results of measurement of proteolytic activity in organomercurial-pre-activated samples, and expressed in nanograms per milliliter (ng/ml). Each dot represents measurement done in a single patient from the respective group. Horizontal lines correspond to mean (bold line) and median (thin line) values for each group. Dashed lines connect respective "before ICS" and "after ICS" values corresponding to their changes following the treatment with inhaled corticosteroids in each patient](CEJI-41-27905-g005){#F0005}

None of tested EBC samples has shown any detectable amounts of amylase.

Discussion {#S0008}
==========

Inhaled corticosteroids are the key component in standard treatment of patients with asthma \[[@CIT0002], [@CIT0031], [@CIT0032]\]. Numerous studies have proven that ICS, when used in asthma exacerbation, effectively reduced clinical symptoms and decreased selected markers of inflammation \[[@CIT0004], [@CIT0033]--[@CIT0036]\]. Furthermore, some authors have demonstrated that ICS treatment in patients with asthma resulted in a decrease in MMP-9 amount in sputum or in mucosal biopsy \[[@CIT0017], [@CIT0018]\].

Surprisingly, in our proof of concept study even high doses of ICS, despite their apparent beneficial effect in reduction of clinical symptoms and significant anti-inflammatory potential, did not reduce the concentration and activity of MMP-9 in exhaled breath condensates. Moreover, in contrast to other report \[[@CIT0015]\], we did not observe any correlation between occurrence of clinical symptoms or their change, and the concentration of MMP-9/EBC in ICS-treated patients.

Several reasons of observed inconsistency could be taken into consideration. Undoubtedly, the main limitation of our proof of concept study is a very small group of patients. Regardless of the noticeable trend, our observation could not be considered as statistically significant and should obviously be verified in a larger group of patients. On the other hand, even despite such small study group we have seen a pronounced effect of ICS treatment on reduction of asthma exacerbation symptoms. The observed reduction of breath shortness and wheezing, or improvement of exercise tolerance after increased doses of ICS correlated with improvement in results of spirometric tests -- FEV~1~ and Tiffeneau-Pinelli index. Noticeably, in laboratory assessments this improvement was clearly associated with a marked decrease in eNO and TNF/EBC levels, but not MMP-9.

Another explanation for observed discrepancies between previously mentioned studies and our data could be various sample sources and different detection systems. In our study, instead of mucosal biopsy or induced sputum, as a material for MMP-9 measurement we have used exhaled breath condensate. This method, due to its non-invasiveness, allows the repetitive sample collection, even in very young children \[[@CIT0037], [@CIT0038]\]. Moreover, it does not require any anesthesia, which may interfere with results of biochemical assessment \[[@CIT0039]\]. The induced sputum, although easily accessible in the majority of adults, may be more problematic in young patients. Besides, sputum contains huge quantities of MMP-9 produced by salivary glands \[[@CIT0029], [@CIT0030]\], which significantly limit reliable assessment of this enzyme, at least in the context of its possible involvement in airway pathologies. Hence, particularly for the assessment of MMP-9, the composition of saliva-free EBC seems to better reflect the current pathological state of the entire respiratory tract \[[@CIT0027]\].

Furthermore, in contrast to previously mentioned reports, which exploited simple assessment of MMP-9 protein by ELISA, in our pilot study we have used a novel immunoenzymatic method, based on colorimetric measurement of MMP-9 activity. Therefore, our results may reproduce the actual *in vivo* activity of this enzyme more precisely than standard ELISA.

Last but not least, the discrepancies between our data and mentioned reports may be explained by a significant difference in the observation period. In contrast to one-year observation by Wang *et al*. \[[@CIT0017]\], our study could possibly be too short to see long-term effects of ICS. However, most recently it has been demonstrated that even prolonged ICS administration, despite good clinical control of asthma symptoms, did not normalize elevated MMP-9 in EBC \[[@CIT0040]\].

Based on observations concerning the decrease in eNO and TNF/EBC, but not MMP-9/EBC, in response to increased doses of ICS, one can speculate that the level of MMP-9 in EBC appears to be independent from eventual inflammatory response. Since inflammatory leukocytes, especially macrophages and neutrophils, are considered as main producers of MMP-9 \[[@CIT0041]\], there arises the question concerning alternative sources of this metalloproteinase. Several candidates have been suggested so far, including respiratory tract epithelium, mucosal mast cells, fibroblasts as well as smooth muscle cells from airway mucosa \[[@CIT0042]--[@CIT0045]\]. Such variety of possible MMP-9 producers may explain the relatively weak or even lack of response to ICS treatment as regards production and activity of this enzyme.

It is plausible that ICS, although effective in reduction of symptoms and inflammatory response in asthma exacerbation, may be not sufficient to fully control the course of disease. Moreover, some authors even suggested that ICS do not protect from long-term structural and functional alterations of the respiratory tract, which are referred to as airway remodeling \[[@CIT0046], [@CIT0047]\]. This assumption may be crucial as regards widespread ICS use in asthma treatment. On the other hand, such uncertainty may be especially important due to a postulated pivotal role of MMP-9 in airway remodeling in asthma \[[@CIT0048]\]. However, the exact role of MMP-9 in airway remodeling still remains unclear. Numerous authors claim that high levels of MMP-9 may destroy ECM in airway mucosa. This damage could stimulate chaotic tissue regeneration, which may result in increased fibrosis and, thus, it would determine a detrimental effect of MMP-9 on disease progression \[[@CIT0049], [@CIT0050]\]. The enthusiasts of the opposite concept suggest that MMP-9 may digest improperly deposited ECM components, and thus it actually might play a protective role against tissue fibrosis and airway remodeling \[[@CIT0051]\]. Therefore, since being critical for the basic strategy of asthma treatment, this issue requires urgent and univocal explanation.
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